These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1153 related articles for article (PubMed ID: 34369992)
1. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992 [TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review. Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459 [TBL] [Abstract][Full Text] [Related]
3. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972 [TBL] [Abstract][Full Text] [Related]
4. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265 [TBL] [Abstract][Full Text] [Related]
5. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? Wang C; Fakih M Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532 [TBL] [Abstract][Full Text] [Related]
6. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833 [TBL] [Abstract][Full Text] [Related]
7. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
8. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663 [TBL] [Abstract][Full Text] [Related]
9. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
10. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280 [TBL] [Abstract][Full Text] [Related]
11. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. Garralda E; Sukari A; Lakhani NJ; Patnaik A; Lou Y; Im SA; Golan T; Geva R; Wermke M; de Miguel M; Palcza J; Jha S; Chaney M; Abraham AK; Healy J; Falchook GS ESMO Open; 2022 Dec; 7(6):100639. PubMed ID: 36493599 [TBL] [Abstract][Full Text] [Related]
12. Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer? Ghiringhelli F; Fumet JD Front Immunol; 2019; 10():1816. PubMed ID: 31447840 [TBL] [Abstract][Full Text] [Related]
13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224 [TBL] [Abstract][Full Text] [Related]
14. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541 [TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. Tintelnot J; Stein A World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527 [TBL] [Abstract][Full Text] [Related]
17. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513 [TBL] [Abstract][Full Text] [Related]
18. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298 [TBL] [Abstract][Full Text] [Related]
20. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors. Cai L; Chen A; Tang D Immunology; 2024 Oct; 173(2):209-226. PubMed ID: 38517066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]